Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Title: 

CHRONIC ORAL PELARGONIDIN ALLEVIATES STREPTOZOTOCIN-INDUCED DIABETIC NEUROPATHIC HYPERALGESIA IN RAT

Type: POSTER
Author(s): MIRSHEKARI M.A.*,ROGHANI MEHRDAD,BALUCHNEJADMOJARAD TOURANDOKHT,KHALILI M.,ARAB MOAZEN S.
 
 *DEPARTMENT OF PHYSIOLOGY, SCHOOL OF BASIC SCIENCES, SHAHED UNIVERSITY, TEHRAN, IRAN
 
Name of Seminar: IRANIAN CONGRESS OF PHYSIOLOGY AND PHARMACOLOGY
Type of Seminar:  CONGRESS
Sponsor:  PHYSIOLOGY AND PHARMACOLOGY SOCIETY, MASHHAD UNIVERSITY OF MEDICAL SCIENCE
Date:  2009Volume 19
 
 
Abstract: 

Diabetes mellitus in some clinical cases is accompanied with hyperalgesia. In this study, we evaluated the effect of chronic pelargonidin (PG) treatment on hyperalgesia in diabetic rat. Male Wistar rats were divided into control, diabetic, PG-treated control, PG (single- and multiple-dose)- treated diabetic, and sodium salisylate (SS)-treated control and diabetics. PG was administered p.o. at a dose of 10 mg/kg on alternate days for 8 weeks. For induction of diabetes, streptozotocin (STZ) was injected i.p. at a single dose of 60 mg/kg. After two months, hyperalgesia were assessed using standard formalin and hot tail immersion tests. Diabetic rats showed a marked chemical and thermal hyperalgesia, indicating that development of diabetic neuropathy and PG treatment (especially multiple-dose) significantly ameliorated the alteration in hyperalgesia (p<0.05-0.01) in diabetic rats as compared to untreated diabetics in both tests. These results clearly suggest the potential of PG in prevention and treatment of diabetic neuropathic hyperalgesia.

 
Keyword(s): PELARGONIDIN, DIABETIC NEUROPATHY, HYPERALGESIA
 
 
Yearly Visit 35   tarjomyar
 
Latest on Blog
Enter SID Blog